Kura Oncology, Inc. (KURA)
After hours:
- GlobeNewswire
Kura Oncology Reports Second Quarter 2022 Financial Results
– Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Preliminary activity observed in KURRENT-HN trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC, first patient dosed in HRAS overexpression cohort – – $450 million in cash, cash equivalents and investments provide runway through 2024 – – Management to host webcast and conference call today at 4:30 p.m. E
- GlobeNewswire
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel titled “Bullseye - Targeted Oncology – In with the New” at 10:20 a.m. ET / 7:20 a.m. PT on Tuesda
- GlobeNewswire
Kura Oncology to Report Second Quarter 2022 Financial Results
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2022 financial results after the close of U.S. financial markets on Wednesday, August 3, 2022. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide
